Adjunct Therapies for Pediatric ARDS: Where are the Data?

Transcription

1 Adjunct Therapies for Pediatric ARDS: Where are the Data? Alexandre T. Rotta, MD, FCCM Professor of Pediatrics, Linsalata Family Endowed Chair in Pediatric Critical Care and Emergency Medicine Rainbow Babies & Children s Hospital Case Western Reserve University, Cleveland, OH

2

3

4

5

6 Pressure-Volume Zones 50 Zone of Volutrauma 40 Volume (ml) Zone of Atelectrauma Pressure (cm H 2 O)

7 Effect of a Protective-Ventilation Strategy on Mortality in the Acute Respiratory Distress Syndrome Amato, MBP, et al. N Engl J Med 1998

8 Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome ARDS Network, N Engl J Med 2000

9 Adjunct Therapies in ARDS HFOV Inhaled Nitric Oxide Corticosteroids Exogenous Surfactant Neuromuscular Blockers Prone Position ETT Suctioning Chest Physiotherapy Epoprostenol 2 -agonists Heliox N-acetylcysteine ECMO 9

10 Adjunct Therapies in ARDS HFOV Inhaled Nitric Oxide Corticosteroids Exogenous Surfactant Neuromuscular Blockers Prone Position ETT Suctioning Chest Physiotherapy Epoprostenol 2 -agonists Heliox N-acetylcysteine ECMO 10

11 Adjunct Therapies in ARDS HFOV Inhaled Nitric Oxide Corticosteroids Exogenous Surfactant Neuromuscular Blockers Prone Position ETT Suctioning Chest Physiotherapy Epoprostenol 2 -agonists Heliox N-acetylcysteine ECMO 11

12 Adjunct Therapies in ARDS Inhaled Nitric Oxide Corticosteroids Exogenous Surfactant Neuromuscular Blockers Prone Position 12

13 Inhaled Nitric Oxide Griffiths MJD, Timothy W. Evans TW. N Engl J Med 2005; 353:

14 Griffiths MJD, Timothy W. Evans TW. N Engl J Med 2005; 353:

15 Griffiths MJD, Timothy W. Evans TW. N Engl J Med 2005; 353:

16

17 Acute Respiratory Distress Syndrome

18 Adhikari NKJ et al, BMJ 2007 Effect of nitric oxide on PaO 2 /FiO 2 ratio at 24 hours

19 Adhikari NKJ et al, BMJ 2007 Effect of nitric oxide on Mortality

20 Dellinger RP, et al. Crit Care Med 1998;26:15 23

21 Inhaled NO in Children with Acute Hypoxemic Respiratory Failure Day RW et al, Chest 1997

22 Dobyns EL, et al. J Pediatr 1999;134:406 12)

23 Dobyns EL, et al. J Pediatr 1999;134:406 12)

24 Dobyns EL, et al. J Pediatr 1999;134:406 12)

25 Dobyns EL, et al. J Pediatr 1999;134:406 12)

26 Dobyns EL, et al. J Pediatr 1999;134:406 12)

27 Patients with OI>25 at enrollment Immunocompromised Patients Dobyns EL, et al. J Pediatr 1999;134:406 12)

28

29

30 Adhikari NKJ et al, Crit Care Med 2013

31 Ruan SY et al, Critical Care Med 2015

32 PALICC Recommendations ino is not recommended for routine use in PARDS. Its use may be considered in patients with documented pulmonary hypertension or severe right ventricular dysfunction. It may be considered in severe cases of PARDS as a rescue from or bridge to extracorporeal life support. When used, assessment of benefit must be undertaken promptly and serially to minimize toxicity and to eliminate continued use without established effect. Tamburro RS, Kneyber MC, for the PALICC Group, 2015

33 How do I Use ino in the PARDS? Rarely, and when forced to Cosmetic therapy: buys hrs of improved oxygenation Start at 20 ppm and attempt to decrease FiO 2 to < 0.6 Monitor frequent ABGs Follow methemoglobin Follow NO 2 measurements Wean by 5 ppm once evidence of improvement Wean by 1 ppm when dose is at 5 ppm Watch for rebound hypoxemia

34 Adjunct Therapies in ARDS Inhaled Nitric Oxide Corticosteroids Exogenous Surfactant Neuromuscular Blockers Prone Position 34

35 Corticosteroids in PARDS No RCTs evaluating glucocorticoids in pediatric ARDS Case reports and small case series Adult data are conflicting

36 36

37 37

38 PALICC Recommendations At this time, corticosteroids cannot be recommended as routine therapy in PARDS. Further study should focus on specific patient populations that are likely to benefit from corticosteroid therapy and specific dosing and delivery regimens. (Strong agreement) Tamburro RS, Kneyber MC, for the PALICC Group, 2015

39 Do I use Steroids in the PARDS? Not routinely Have used methylprednisolone for the very rare and occasional patient if I can find a reasonable justification ARDS in a patient with chronic lung disease Last effort when family not agreeable to ECLS escalation

40 Adjunct Therapies in ARDS Inhaled Nitric Oxide Corticosteroids Exogenous Surfactant Neuromuscular Blockers Prone Position 40

41 Surfactant Control Surfactant 42 children in 8 ICUs Well tolerated Earlier extubation (4.2 days sooner) Earlier discharge from ICU (5 days sooner) No difference in mortality Willson DF, et al Crit Care Med 1999;27:

42 42

43 43

44 Proportion of Calfactant Compared With Placebo Patients Successfully Extubated in the 28 Days After Study Entry

45 45

46 46

47 Thomas NJ et al. Pediatr Crit Care Med,

48 PALICC Recommendations At this time, surfactant therapy cannot be recommended as routine therapy in PARDS. Further study should focus on specific patient populations that may be likely to benefit and specific dosing and delivery regimens. (Strong agreement) Tamburro RS, Kneyber MC, for the PALICC Group, 2015

49 Do I use Surfactant in the PARDS? Not routinely Have used exogenous surfactant in children who are stuck on ECLS with non-recruitable lungs. Have used it as part of a clinical trial

50 Adjunct Therapies in ARDS Inhaled Nitric Oxide Corticosteroids Exogenous Surfactant Neuromuscular Blockers Prone Position 50

51

52 52

53

54 PALICC Recommendations We recommend that if sedation alone is inadequate to achieve effective mechanical ventilation, NMB should be considered. When used, pediatric patients with PARDS should receive minimal yet effective NMB with sedation to facilitate their tolerance to mechanical ventilation and to optimize oxygen delivery, oxygen consumption, and work of breathing. (Strong agreement) Valentine SL, for the PALICC Group, 2015

55 PALICC Recommendations NMB use should be monitored and titrated to goal Consider a daily holiday Clinical trials should report their NMB strategy Further studies are needed (Strong agreement) Valentine SL, for the PALICC Group, 2015

56 Do I use NMB in the PARDS? Yes, my usage matches the PALICC recommendations

57 Adjunct Therapies in ARDS Inhaled Nitric Oxide Corticosteroids Exogenous Surfactant Neuromuscular Blockers Prone Position 57

58 Prone Positioning Supine Prone

59 Gattinoni L, et al. NEJM 2001;234:568 73

60

61

62

63

64

65 65

66 66

67

68

69 PALICC Recommendations Prone positioning cannot be recommended as routine therapy in PARDS. However, it should be considered an option in cases of severe PARDS. Further pediatric study is warranted, particular study stratifying on the basis of severity of lung injury. (Weak agreement) Tamburro RS, Kneyber MC, for the PALICC Group, 2015

70 Do I use Prone Positioning in the PARDS? Yes, my usage matches the PALICC recommendations

71 Adjunct Therapies in ARDS HFOV Inhaled Nitric Oxide Corticosteroids Exogenous Surfactant Neuromuscular Blockers Prone Position ETT Suctioning Chest Physiotherapy Epoprostenol 2 -agonists Heliox N-acetylcysteine ECMO 71

72 Thank You! 72